Idiopathic Pulmonary Fibrosis (IPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Idiopathic Pulmonary Fibrosis (IPF) Market Outlook

Thelansis’s “Idiopathic Pulmonary Fibrosis (IPF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Pulmonary Fibrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic condition characterized by lung scar tissue, developing gradually over several years and without any known cause. The primary symptoms associated with IPF are exercise-induced shortness of breath and a persistent, dry cough. IPF falls under interstitial lung disease (ILD), more accurately referred to as diffuse parenchymal lung disease (DPLD). Within this broad classification of lung disorders, IPF belongs explicitly to a subgroup known as idiopathic interstitial pneumonia (IIP). The typical age of presentation for IPF is around 66 years. Initial symptoms often include exertional breathlessness and persistent dry cough. When examining the lungs of IPF patients, healthcare providers frequently detect early inspiratory crackling sounds, mainly in the lower posterior lung regions. Approximately 50% of IPF patients may also exhibit clubbing of the fingers. Over time, exertional dyspnea worsens progressively, spanning months to years. IPF can be identified through high-resolution computed tomography, which reveals peripheral subpleural reticular opacities in the lower lung lobes, often accompanied by subpleural honeycomb changes. Differential diagnosis involves distinguishing IPF from other idiopathic interstitial pneumonias, connective tissue diseases such as systemic sclerosis, polymyositis, and rheumatoid arthritis, as well as various forms of autoimmune disorders and chronic hypersensitivity pneumonitis. Environmental and sometimes occupational exposures are also taken into consideration. Current international guidelines recommend two medications, pirfenidone and nintedanib, for treating IPF. These medications are known to slow down the progression of the disease, as evidenced by a roughly 50% reduction in the decline of forced vital capacity. They are considered safe and effective.

• IPF affects approximately 132,000 individuals in the United States, with around 50,000 new diagnoses made each year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: